Brokerages Anticipate Aduro BioTech Inc (ADRO) Will Post Earnings of -$0.36 Per Share
Equities research analysts predict that Aduro BioTech Inc (NASDAQ:ADRO) will announce ($0.36) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for Aduro BioTech’s earnings. The lowest EPS estimate is ($0.46) and the highest is ($0.30). Aduro BioTech reported earnings per share of ($0.44) during the same quarter last year, which indicates a positive year over year growth rate of 18.2%. The firm is scheduled to report its next quarterly earnings results on Wednesday, March 7th.
On average, analysts expect that Aduro BioTech will report full-year earnings of ($1.28) per share for the current financial year, with EPS estimates ranging from ($1.39) to ($1.22). For the next financial year, analysts forecast that the business will post earnings of ($1.35) per share, with EPS estimates ranging from ($1.66) to ($0.78). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that that provide coverage for Aduro BioTech.
Aduro BioTech (NASDAQ:ADRO) last posted its earnings results on Tuesday, October 31st. The biotechnology company reported ($0.33) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.30) by ($0.03). Aduro BioTech had a negative return on equity of 39.28% and a negative net margin of 548.92%. The business had revenue of $3.79 million during the quarter, compared to analyst estimates of $4.04 million. During the same quarter in the prior year, the company earned ($0.54) EPS. The company’s revenue was up .0% on a year-over-year basis.
A number of research firms recently weighed in on ADRO. HC Wainwright set a $18.00 target price on shares of Aduro BioTech and gave the stock a “buy” rating in a report on Wednesday, November 1st. Oppenheimer began coverage on shares of Aduro BioTech in a report on Monday, October 30th. They issued a “buy” rating and a $15.00 target price on the stock. William Blair restated an “outperform” rating on shares of Aduro BioTech in a report on Monday, October 2nd. Canaccord Genuity set a $30.00 target price on shares of Aduro BioTech and gave the stock a “buy” rating in a report on Thursday, August 3rd. Finally, BidaskClub lowered shares of Aduro BioTech from a “hold” rating to a “sell” rating in a research note on Tuesday, August 8th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company. Aduro BioTech currently has an average rating of “Buy” and a consensus target price of $19.14.
In other Aduro BioTech news, CEO Stephen T. Isaacs sold 40,000 shares of the stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $10.78, for a total value of $431,200.00. Following the completion of the sale, the chief executive officer now owns 213,921 shares in the company, valued at approximately $2,306,068.38. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Stephen T. Isaacs sold 16,400 shares of the stock in a transaction dated Friday, November 10th. The shares were sold at an average price of $7.96, for a total transaction of $130,544.00. Following the completion of the sale, the chief executive officer now owns 190,321 shares of the company’s stock, valued at approximately $1,514,955.16. The disclosure for this sale can be found here. In the last quarter, insiders sold 187,880 shares of company stock valued at $1,765,881. Company insiders own 6.60% of the company’s stock.
A number of large investors have recently bought and sold shares of ADRO. Legal & General Group Plc increased its stake in Aduro BioTech by 11.2% in the 2nd quarter. Legal & General Group Plc now owns 10,359 shares of the biotechnology company’s stock valued at $118,000 after buying an additional 1,043 shares during the last quarter. Fox Run Management L.L.C. bought a new position in shares of Aduro BioTech during the 3rd quarter valued at approximately $127,000. Tudor Investment Corp ET AL grew its position in shares of Aduro BioTech by 34.8% during the 1st quarter. Tudor Investment Corp ET AL now owns 15,436 shares of the biotechnology company’s stock valued at $166,000 after acquiring an additional 3,984 shares during the period. Parametric Portfolio Associates LLC grew its position in shares of Aduro BioTech by 15.9% during the 1st quarter. Parametric Portfolio Associates LLC now owns 15,424 shares of the biotechnology company’s stock valued at $166,000 after acquiring an additional 2,119 shares during the period. Finally, SG Americas Securities LLC bought a new position in shares of Aduro BioTech during the 3rd quarter valued at approximately $167,000. Hedge funds and other institutional investors own 45.19% of the company’s stock.
Aduro BioTech (ADRO) traded up $0.05 on Tuesday, hitting $9.55. 675,078 shares of the company were exchanged, compared to its average volume of 406,297. Aduro BioTech has a 12 month low of $6.01 and a 12 month high of $14.05.
Aduro BioTech Company Profile
Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aduro BioTech Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech Inc and related companies with MarketBeat.com's FREE daily email newsletter.